Physician profile
Stephen N Lipsky
NPI 1477550895
$4,340.29
in general payments reported to CMS, 2019-2025
27 companies · $231 in 2025
The $231 reported for 2025 was more than what a typical Pediatric Ophthalmology and Strabismus Specialist provider received nationally (typical 2025 total: $118).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $431 · 2020: $338 · 2021: $1,722 · 2022: $547 · 2023: $686 · 2024: $386 · 2025: $231.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,303.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,302.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Topcon Healthcare, INC. | $1,561.97 | 2021 | |
| Recordati_rare_diseases_inc. | $246.73 | 2021-2023 | Cystadrops |
| Alcon Vision LLC | $227.90 | 2020-2025 | Clareon |
| Dompe US, INC. | $183.49 | 2023-2025 | Oxervate |
| Abbvie INC. | $153.94 | 2022-2024 | |
| Sight Sciences, INC. | $146.59 | 2023 | Omni Surgical System |
| Biotissue Holdings INC. | $143.65 | 2023 | |
| Amgen INC. | $136.91 | 2024 | Tepezza |
| Johnson & Johnson Surgical Vision, INC. | $136.81 | 2019 | |
| Genentech USA, INC. | $130.18 | 2022 | |
| Carl Zeiss Meditec, INC. | $129.16 | 2019 | |
| Eyepoint US, INC. | $127.79 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $126.33 | 2019-2021 | |
| Rxsight INC | $124.95 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $121.09 | 2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $104.63 | 2024 | Izervay |
| Glaukos Corporation | $104.12 | 2020 | |
| Bausch & Lomb Americas INC. | $89.46 | 2022 | |
| Coopervision INC. | $62.50 | 2020-2023 | Misight Contact Lens |
| Leadiant Biosciences, INC. | $57.52 | 2024-2025 | Cystaran |
| Horizon Therapeutics Plc | $47.89 | 2023 | Tepezza |
| Shire North American Group INC | $43.78 | 2019 | |
| Eyevance Pharmaceuticals LLC | $35.25 | 2019 | |
| Spark Therapeutics, INC. | $32.80 | 2019-2022 | |
| Allergan, INC. | $23.30 | 2021 | |
| Johnson & Johnson Vision Care, INC. | $23.12 | 2021 | |
| Eusa Pharma (US) LLC | $18.43 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Lipsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.